Yong-Chan Kim
Directeur/Bestuurslid bij BAUDAX BIO, INC.
Vermogen: 32 $ op 31-05-2024
Actieve functies van Yong-Chan Kim
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BAUDAX BIO, INC. | Directeur/Bestuurslid | 03-07-2023 | - |
| Independent Dir/Board Member | 03-07-2023 | - | |
TeraImmune, Inc.
 TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Directeur/Bestuurslid | 01-04-2019 | - |
| Algemeen Directeur | 01-04-2019 | - | |
| Oprichter | 01-01-2016 | - |
Loopbaan van Yong-Chan Kim
Opleiding van Yong-Chan Kim
| Chungnam National University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Zuid-Korea | 2 |
Operationeel
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BAUDAX BIO, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |
- Beurs
- Insiders
- Yong-Chan Kim
- Ervaring
